Zonimid 25 Capsule contains Zonisamide 25 mg, an anticonvulsant medication primarily indicated for the management of partial seizures in patients with epilepsy. Zonisamide exerts its therapeutic effect by blocking voltage-dependent sodium and T-type calcium channels, thereby stabilizing neuronal membranes and suppressing abnormal electrical activity in the brain. This mechanism helps reduce the frequency and severity of seizures. Zonimid 25 is typically prescribed as adjunctive therapy in adults and pediatric patients over the age of six years who have refractory partial seizures. The capsule formulation allows for convenient oral administration with good bioavailability. Dosage should be individualized based on clinical response and tolerability, with gradual titration to minimize adverse effects. Common side effects may include dizziness, somnolence, headache, anorexia, and gastrointestinal disturbances. Rare but serious adverse reactions such as metabolic acidosis, hypersensitivity reactions, and renal calculi have been reported, warranting regular monitoring during therapy. Caution is advised in patients with sulfonamide allergy, hepatic or renal impairment. Zonimid 25 should be used under strict medical supervision, with periodic evaluation to assess efficacy and safety. Patients are advised not to discontinue therapy abruptly to avoid precipitating seizures.